drugset / Trial / NCT00093522

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

NCT00093522

Phase 2 Unknown 28 enrolled St. Luke's Medical Center
RandomizedTreatment

Summary

RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with fludarabine may kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and fludarabine to see how well they work compared to vaccine therapy alone in treating patients with stage IV kidney cancer.

Timeline

Start
2004-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludarabine Small molecule Intravenous
Subject autologous tumor cell vaccine Vaccine
Subject therapeutic autologous dendritic cells Vaccine
Background keyhole limpet hemocyanin Vaccine

Indications